Medical device producers, pharmaceutical contract manufacturers and the life science sector are the main drivers of this growth
The global bioburden testing market is expected to reach US$565.6m by 2019, a rise from an estimated US$354.4m in 2014, representing a 9.8% compound annual growth rate (CAGR) over that period, according to a new report offered by MarketsandMarkets.
Major factors contributing to the growth of the global bioburden testing market include the growing medical device industry, changing trends in the pharmaceutical and biotechnology industries, increasing food safety concerns and a strong trend of R&D investments in life sciences, and increasing product recalls due to microbial contamination.
The CMOs segment is expected to grow at the highest CAGR in the coming five years. Growth in this segment will be driven by the rising demand for cost-effective alternatives for manufacturing in emerging as well as developed countries.
However, the high cost of instruments and complex and time-consuming regulatory standards, which lengthen the approval time for new methods, may hinder the growth of this market in some countries.
The report covers the market for bioburden testing instruments such as PCR or Microscopes, and consumables (kits and reagents), as well as tests (aerobic, anaerobic, fungi and spore), and the applications for their use.
Details of Bioburden Testing Market by Product, Test, Application & End User - Forecast to 2019 can be found at www.researchandmarkets.com/research/6wjpd6/bioburden_testing.